240 related articles for article (PubMed ID: 22272254)
1. High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase.
Goldin E; Zheng W; Motabar O; Southall N; Choi JH; Marugan J; Austin CP; Sidransky E
PLoS One; 2012; 7(1):e29861. PubMed ID: 22272254
[TBL] [Abstract][Full Text] [Related]
2. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.
Tropak MB; Kornhaber GJ; Rigat BA; Maegawa GH; Buttner JD; Blanchard JE; Murphy C; Tuske SJ; Coales SJ; Hamuro Y; Brown ED; Mahuran DJ
Chembiochem; 2008 Nov; 9(16):2650-62. PubMed ID: 18972510
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.
Maegawa GH; Tropak MB; Buttner JD; Rigat BA; Fuller M; Pandit D; Tang L; Kornhaber GJ; Hamuro Y; Clarke JT; Mahuran DJ
J Biol Chem; 2009 Aug; 284(35):23502-16. PubMed ID: 19578116
[TBL] [Abstract][Full Text] [Related]
4. Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells.
Trapero A; Alfonso I; Butters TD; Llebaria A
J Am Chem Soc; 2011 Apr; 133(14):5474-84. PubMed ID: 21413704
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.
Babajani G; Tropak MB; Mahuran DJ; Kermode AR
Mol Genet Metab; 2012 Jul; 106(3):323-9. PubMed ID: 22592100
[TBL] [Abstract][Full Text] [Related]
6. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
[TBL] [Abstract][Full Text] [Related]
7. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
[TBL] [Abstract][Full Text] [Related]
8. The N370S (Asn370-->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C.
Salvioli R; Tatti M; Scarpa S; Moavero SM; Ciaffoni F; Felicetti F; Kaneski CR; Brady RO; Vaccaro AM
Biochem J; 2005 Aug; 390(Pt 1):95-103. PubMed ID: 15826241
[TBL] [Abstract][Full Text] [Related]
9. Optimization and validation of two miniaturized glucocerebrosidase enzyme assays for high throughput screening.
Urban DJ; Zheng W; Goker-Alpan O; Jadhav A; Lamarca ME; Inglese J; Sidransky E; Austin CP
Comb Chem High Throughput Screen; 2008 Dec; 11(10):817-24. PubMed ID: 19075603
[TBL] [Abstract][Full Text] [Related]
10. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
Lieberman RL; Wustman BA; Huertas P; Powe AC; Pine CW; Khanna R; Schlossmacher MG; Ringe D; Petsko GA
Nat Chem Biol; 2007 Feb; 3(2):101-7. PubMed ID: 17187079
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.
Yap TL; Gruschus JM; Velayati A; Westbroek W; Goldin E; Moaven N; Sidransky E; Lee JC
J Biol Chem; 2011 Aug; 286(32):28080-8. PubMed ID: 21653695
[TBL] [Abstract][Full Text] [Related]
12. Novel compounds that reverse the disease phenotype in Type 2 Gaucher disease patient-derived cells.
Childers W; Fan R; Martinez R; Colussi DJ; Melenski E; Liu Y; Gordon J; Abou-Gharbia M; Jacobson MA
Bioorg Med Chem Lett; 2020 Jan; 30(2):126806. PubMed ID: 31757667
[TBL] [Abstract][Full Text] [Related]
13. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.
Zheng W; Padia J; Urban DJ; Jadhav A; Goker-Alpan O; Simeonov A; Goldin E; Auld D; LaMarca ME; Inglese J; Austin CP; Sidransky E
Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13192-7. PubMed ID: 17670938
[TBL] [Abstract][Full Text] [Related]
14. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease.
Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG
Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891
[TBL] [Abstract][Full Text] [Related]
15. Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease.
Serra-Vinardell J; Díaz L; Gutiérrez-de Terán H; Sánchez-Ollé G; Bujons J; Michelakakis H; Mavridou I; Aerts JM; Delgado A; Grinberg D; Vilageliu L; Casas J
Int J Biochem Cell Biol; 2014 Sep; 54():245-54. PubMed ID: 25084554
[TBL] [Abstract][Full Text] [Related]
16. Deficiency of Glucocerebrosidase Activity beyond Gaucher Disease: PSAP and LIMP-2 Dysfunctions.
Pavan E; Peruzzo P; Cattarossi S; Bergamin N; Bordugo A; Sechi A; Scarpa M; Biasizzo J; Colucci F; Dardis A
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928321
[TBL] [Abstract][Full Text] [Related]
17. The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase.
Fog CK; Zago P; Malini E; Solanko LM; Peruzzo P; Bornaes C; Magnoni R; Mehmedbasic A; Petersen NHT; Bembi B; Aerts JFMG; Dardis A; Kirkegaard T
EBioMedicine; 2018 Dec; 38():142-153. PubMed ID: 30497978
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.
Yang C; Rahimpour S; Lu J; Pacak K; Ikejiri B; Brady RO; Zhuang Z
Proc Natl Acad Sci U S A; 2013 Jan; 110(3):966-71. PubMed ID: 23277556
[TBL] [Abstract][Full Text] [Related]
19. Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.
Orwig SD; Tan YL; Grimster NP; Yu Z; Powers ET; Kelly JW; Lieberman RL
Biochemistry; 2011 Dec; 50(49):10647-57. PubMed ID: 22047104
[TBL] [Abstract][Full Text] [Related]
20. ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease.
Tan YL; Genereux JC; Pankow S; Aerts JM; Yates JR; Kelly JW
Chem Biol; 2014 Aug; 21(8):967-76. PubMed ID: 25126989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
